Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FibroCann
RBR-4bhmm7yPhase 3Not yet recruiting
- Sponsor
- Aura Pharma
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol and dronabinol in fibromyalgia (FM) (4 arms), sponsored by Aura Pharma. Primary endpoint: Not reported. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
cannabidioldronabinol
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on RBR-4bhmm7y.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4bhmm7y.